Finger On The Pulse: The State Of Biopharma Leadership

Pharma Leaders Focus On Providing A Clear Vision In The Face Of Uncertainty

In Vivo asked six biopharma figureheads to share their thoughts on the state of leadership in the life sciences space, exploring the qualities of a great leader, how recent years have shaped this role within the industry and the challenges ahead.

Graphic featuring headshots of all the interviewees
Roivant CEO Matt Gline, UPS Healthcare VP of sales Cathy O'Brien, Pfizer SVP of commercial strategy & innovation Andy Schmeltz, Celltrion USA CEO Tom Nusbickel, Ipsen chief business officer Phillipe Lopes-Fernandes, Sandoz CEO Richard Saynor • Source: Shutterstock

Recent years have seen the role of a biopharma industry leader alter drastically, with events like the COVID-19 pandemic and the war in Ukraine reshaping the day-to-day operations of the sector, from drug distribution to the dominance of remote working. In Vivo caught up with six leaders across the space – from big pharma to generics and biosimilars developers – to get their take on the changing role of a biopharma industry leader.

Matt Gline, CEO of growing biotech company Roivant Sciences Ltd., said: “That’s a hard question and I still spend...

More from Leadership

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.